泰索帝联合塞来昔布对肺腺癌细胞增殖的影响  

Effect of Taxotere Combination with Celecoxib on Proliferation of NSCLC Cell

作　　者：韩亮[1] 李薇[1] 束永前[1] 

机构地区：[1]南京医科大学第一附属医院肿瘤生物治疗中心,210029

出　　处：《实用癌症杂志》2006年第2期130-133,共4页The Practical Journal of Cancer

摘　　要：目的探讨泰索帝、塞来昔布单药以及联合用药对非小细胞肺癌细胞株A549增殖及凋亡的影响。方法以人NSCLC细胞株A549作为研究对象,采用MTT,免疫组化以及FCM检测泰索帝和塞来昔布对非小细胞肺癌A549细胞增殖、细胞凋亡、细胞周期和COX-2蛋白表达的影响。结果泰索帝在体外对NSCLC细胞株A549的生长抑制作用呈剂量、时间依赖性,48h最高65%,最低10%,联合塞来昔布(12.5μmol/l,25μmol/l)可以提高泰索帝的抑制率;经高剂量塞来昔布组(>50μmol/l)处理的细胞COX-2蛋白表达呈阴性,而低剂量组(12.5μmol/l,25μmol/l)以及联合用药组细胞COX-2蛋白表达呈阳性;塞来昔布(12.5μmol/l,25μmol/l)作用后,G0/G1期细胞比例增加,S、G2/M期比例下降,联合泰索帝可以提高细胞的凋亡率。结论泰索帝在体外对非小细胞肺癌细胞株的生长有明显的抑制作用,联合塞来昔布可以提高抑制率,诱导细胞凋亡,影响细胞周期的分布,但不是通过影响细胞内环氧化酶-2蛋白表达这一途径实现。Objective To study the effects of Taxotere,Celecoxib and the combination of both on proleferation and apoptosis of NSCLC cell. Methods Investigate the effect of Taxotere, Celecoxib and the combination of both on proliferation of NSCLC A549 by MTT assays. Detect the change of apoptosis, cell cycle and the expression of COX-2 protein using flow cytometry analysis and immunocytochemistry,respectively. Results Taxotere could inhibit the proliferation of A549 cell by a time- and dose-dependent manner and the combination with Celecoxib（12.5 μmol/1,25 μmol/1） could improve the inhibition. After 48 h of incubation Mth Taxotere, the highest inhibitory rate of the cell is 65 % and the lowest inhibitory rate is 10 %. High-dose celecoxib （ 〉 50 μmol/l） can suppress COX-2 gene expression, while positive response was found in low-dose celecoxib （12.5 μmol/l, 25 μmol/1） and the combination. Celecoxib can increase the percentage of cell in G0/G1 and decrease that in S and C-2/M. The apoptosis rate of cell increased after Celecoxib combined with Taxotere. Conclusion Taxotere could inhibit effectively the growth of A549 cell lines in vitro and the combination with Celecoxib could improve the inhibition through induceing apoptosis and influencing the distribution of cell cycle, but had no significant influence in the expression of COX-2 protein.

关 键 词：肺腺癌 泰索帝 塞来昔布 

分 类 号：R734.2[医药卫生—肿瘤]